FDA Inspection
Bristol-Myers Squibb CompanyBristol-Myers Squibb Company – FDA Inspection, Jan 25, 2017
Record Details
This FDA Inspection record concerns Bristol-Myers Squibb Company, with an inspection on January 25, 2017, issued by the New Jersey District Office, covering human drugs.
View Company Profile
ID · dca59277-2365-422a-9226-e084019c8687
Inspection Facts
- Inspection number
- 1000482
- FDA center
- Human Drugs
- Project area
- Postmarket Surv. and Epidemiology
- Outcome
- Form 483 issued
FDA Citations
1- 21 CFR 314.80(c)(1)(i)Late submission of 15-day report
Full citation text and observation details available on the Dashboard.
Other FDA inspections of Bristol-Myers Squibb Company
16| Date | Classification | Office | Project area |
|---|---|---|---|
| June 23, 2026 | Not classified | New Jersey District Office | |
| July 18, 2025 | Not classified | New Jersey District Office | |
| December 6, 2024 | VAI | New Jersey District Office | Postmarketing Surveillance and Epidemiology: Human Drugs |
| September 6, 2024 | NAI | Center for Drug Evaluation and Research | Bioresearch Monitoring |
| January 31, 2024 | NAI | Center for Drug Evaluation and Research | Bioresearch Monitoring |
Other documents for Bristol-Myers Squibb Company
- FDA Inspection 1327472 - 2026-06-23
- FDA Inspection 1275526 - 2025-07-18
- FDA Inspection 1236864 - 2024-12-06
- FDA Inspection 1247735 - 2024-09-06
- FDA Inspection 1228973 - 2024-01-31
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.